碳青霉烯类耐药铜绿假单胞菌感染及预后的风险因素研究进展  

Research progress on risk factors of carbapenems resistant Pseudomonas aeruginosa infection and prognosis

作　　者：韩萍 赵建清[1] 张伟[2] 雷春梅 HAN Ping;ZHAO Jianqing;ZHANG Wei;LEI Chunmei(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Hebei North University,Hebei Province,Zhangjiakou 075000,China;Central Laboratory,the First Affiliated Hospital of Hebei North University,Hebei Province,Zhangjiakou 075000,China)

机构地区：[1]河北北方学院附属第一医院呼吸与危重症医学科,河北张家口075000 [2]河北北方学院附属第一医院中心实验室,河北张家口075000

出　　处：《中国医药导报》2025年第4期56-60,共5页China Medical Herald

基　　金：河北省自然科学基金资助项目(C2022405023)。

摘　　要：铜绿假单胞菌是一种重要的院内致病菌,可引起各种感染,通常难以治疗和根除。碳青霉烯类抗生素是一线广谱抗生素耐药铜绿假单胞菌的最后手段,被引入治疗严重的多重耐药铜绿假单胞菌感染,但最终导致全球碳青霉烯类耐药铜绿假单胞菌(CRPA)激增。目前CRPA的治疗非常有限,部分感染者可发展为重症,甚至死亡。本文从CRPA感染风险因素(重症监护室、低白蛋白血症、侵入性操作、住院时间、抗生素暴露史和合并其他病原菌感染等)、预后风险因素(机械通气、中性粒细胞减少等)及评估预后风险的工具(Charlson合并症指数、Pitt菌血症评分等)方面对国内外相关的最新研究进展进行综述,以期为临床治疗CRPA提供参考。Pseudomonas aeruginosa is an important nosocomial pathogen that can cause a variety of infections,is often difficult to treat and eradicate.Carbapenems antibiotics are last resort for first-line broad-spectrum antibiotic resistant Pseudomonas aeruginosa,introduced to treat severe multidrug-resistant Pseudomonas aeruginosa infections,but ultimately leading to a global surge in carbapenem resistant Pseudomonas aeruginosa(CRPA).At present,treatment of CRPA is very limited,some infected individuals may develop severe symptoms or even die.This article reviews latest research progress on CRPA infection risk factors(intensive care unit,hypoalbuminemia,invasive procedures,length of hospital stay,history of antibiotic exposure,and concurrent infections with other pathogens,etc.),prognostic risk factors(mechanical ventilation,neutropenia,etc.),and tools for assessing prognostic risk(Charlson comorbidity index,Pitt bacteremia score,etc.)both domestically and internationally,providing reference for clinical treatment of CRPA.

关 键 词：碳青霉烯类 铜绿假单胞菌 感染 预后 风险因素 

分 类 号：R378.991[医药卫生—病原生物学]